Damase-Michel C, Montastruc J L, Tran M A, Gharib C, Geelen G, Montastruc P
Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse.
Eur J Pharmacol. 1990 Aug 2;184(1):179-83. doi: 10.1016/0014-2999(90)90680-5.
The effects of quinpirole, a specific dopamine D2 receptor agonist, were investigated on cardiovascular responses and plasma levels of catecholamines and vasopressin in two groups of conscious dogs: (1) control dogs and (2) dogs with diabetes insipidus (i.e. animals surgically deprived of vasopressin). In normal dogs, i.v. quinpirole (30 micrograms/kg) elicited a decrease in blood pressure associated with a rise in both plasma catecholamine and vasopressin levels. In dogs with diabetes insipidus, i.v. quinpirole induced a more marked decrease in blood pressure than in normal dogs. Quinpirole did not change plasma noradrenaline and vasopressin levels in dogs with diabetes insipidus. The present study demonstrates that the decrease in blood pressure elicited by quinpirole is associated with an increase in vasopressin release, which counteracts the hypotensive effect of the the dopamine D2 receptor agonist.
研究了特异性多巴胺D2受体激动剂喹吡罗对两组清醒犬心血管反应、儿茶酚胺血浆水平和血管加压素的影响：（1）对照犬和（2）尿崩症犬（即手术切除血管加压素的动物）。在正常犬中，静脉注射喹吡罗（30微克/千克）导致血压下降，同时血浆儿茶酚胺和血管加压素水平升高。在尿崩症犬中，静脉注射喹吡罗引起的血压下降比正常犬更明显。喹吡罗对尿崩症犬的血浆去甲肾上腺素和血管加压素水平没有影响。本研究表明，喹吡罗引起的血压下降与血管加压素释放增加有关，血管加压素释放增加抵消了多巴胺D2受体激动剂的降压作用。
